Dyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. Baird

Robert W. Baird initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a report published on Friday morning, MarketBeat reports. The brokerage issued an outperform rating and a $46.00 price objective on the stock.

A number of other research firms have also recently commented on DYN. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Stock Up 0.5 %

Shares of Dyne Therapeutics stock opened at $25.73 on Friday. Dyne Therapeutics has a 52-week low of $11.51 and a 52-week high of $47.45. The firm’s 50 day moving average price is $30.39 and its 200-day moving average price is $35.20. The company has a market cap of $2.62 billion, a P/E ratio of -7.23 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts forecast that Dyne Therapeutics will post -3.45 EPS for the current fiscal year.

Insider Activity

In other news, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The trade was a 6.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Insiders sold a total of 180,046 shares of company stock valued at $6,300,265 in the last quarter. 20.77% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of DYN. SG Americas Securities LLC purchased a new stake in Dyne Therapeutics in the 2nd quarter worth $217,000. Nisa Investment Advisors LLC increased its stake in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Dyne Therapeutics by 52.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company’s stock worth $10,993,000 after purchasing an additional 107,233 shares during the last quarter. Legato Capital Management LLC lifted its stake in Dyne Therapeutics by 35.3% in the 2nd quarter. Legato Capital Management LLC now owns 15,480 shares of the company’s stock valued at $546,000 after buying an additional 4,035 shares in the last quarter. Finally, Lisanti Capital Growth LLC boosted its holdings in Dyne Therapeutics by 22.5% in the 2nd quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company’s stock worth $3,746,000 after buying an additional 19,530 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.